# A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

> **NCT07719855** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 652 (estimated)

## Conditions studied

- Follicular Lymphoma ( FL)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** obinutuzumab
- **DRUG:** Lenalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Vincristine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT07719855
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2030-07
- **Final completion:** 2033-12
- **Target enrollment:** 652 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719855, "A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07719855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*